Press Releases
Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase...
Press Releases
FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended that clinical data included in...
News
Discrepant analyses of industry-sponsored clinical trials
Internal pharmaceutical company documents detailing the planned and completed analyses for clinical trials do not always match the publically available report of the...
Press Releases
Regional Cancer Care Associates Expands Footprint in New Jersey
Regional Cancer Care Associates (RCCA), New Jersey’s largest oncology physician network and one of the largest in the nation, is pleased to announce...
News
Clinical trials with nonblinded outcome assessors have high observer bias
A new study of randomized clinical trials found significant observer bias toward a more beneficial treatment effect in nonblinded trials when the researcher...
Press Releases
Direct Flow Medical Receives CE Mark for Transcatheter Aortic Heart Valve System That Virtually Eliminates Aortic Regurgitation
Direct Flow Medical, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, announced that it has received CE Mark (Conformité Européenne)...
Drug Research
Dr. Reddy’s introduces Desloratadine ODT in US
Dr. Reddy's Laboratories has received the FDA approval and introduced Desloratadine orally disintegrating tablets (ODT) in 2.5mg and 5mg strengths in the US....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read